Bioorganic and Medicinal Chemistry Letters p. 351 - 355 (2004)
Update date:2022-08-02
Topics:
Fraley, Mark E.
Arrington, Kenneth L.
Buser, Carolyn A.
Ciecko, Patrice A.
Coll, Kathleen E.
Fernandes, Christine
Hartman, George D.
Hoffman, William F.
Lynch, Joseph J.
McFall, Rosemary C.
Rickert, Keith
Singh, Romi
Smith, Sheri
Thomas, Kenneth A.
Wong, Bradley K.
Modifications to the basic side-chain of early lead structures of the indolyl quinolinone class of KDR kinase inhibitors resulted in improved pharmacokinetic and ancillary profiles. Specifically, compounds bearing 5-amido- and 5-sulphonamido-indolyl substituents exhibited lower plasma clearance and weaker binding affinity for the IKr potassium channel hERG. 2003 Elsevier Science Ltd. All rights reserved.
View MoreQINGDAO ON-BILLION INDUSTRAIL CO.,LTD
website:http://www.obn.com.cn
Contact:+86-15005320811 +86-532-80681989
Address:F35 Parkson Mansion No.44-60 Zhongshan Rd.
shanghai Tauto Biotech Co., Ltd
website:http://www.tautobiotech.com/en/index.htm
Contact:+86-21-51320588 ext. 8025
Address:No. 326, Aidisheng Rd , Zhangjiang Hi-tech Park, Shanghai , P.R.CHINA
Xian Changyue Biological Technology Co., Ltd.
website:https://www.xachangyue.com/
Contact:+86-029-62886900
Address:Keji Road NO.70
Shanghai KFSL Pharmaceutical Technology Co.,Ltd.
Contact:+86-21-39971718
Address:859 jiadingchengliu shanghai
Changyi Xinxing Technology Development Co., Ltd.
Contact:0086-510-86651065(Time Zone:8),86651656
Address:94 Yingbinxilu WestRoad, Huangtu Town, Jiangyin City, Jiangsu, China
Doi:10.1039/d0gc00383b
(2020)Doi:10.1002/hlca.19730560728
(1973)Doi:10.3987/com-02-s9
(2003)Doi:10.1007/BF00957087
(1988)Doi:10.1002/chem.201301776
(2013)Doi:10.1021/bi00750a009
(1973)